PATH's enterprise AI edge and valuation advantage over APP make it the smarter buy in this AI-driven tech faceoff.

UiPath stands out with improving sales momentum, profitability, and a raised full-year outlook. Read why I remain bullish ...

PATH trades well below peers like NOW and PEGA, despite leading RPA adoption across finance, healthcare, and logistics.

UiPath's market leadership in the RPA market remains compelling, significantly aided by the growing ARR and the rich cash ...

UiPath PATH, a key player in the robotic process automation (“RPA”) market, is trading at a forward 12-month price-to-sales (P/S) ratio of 4.12X, significantly below the industry average of 5 ...

UiPath (PATH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

UiPath PATH, a key player in the robotic process automation (“RPA”) market, is trading at a forward 12-month price-to-sales (P/S) ratio of 4.12X, significantly below the industry average of 5.75X.

UiPath (PATH) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

In the latest close session, UiPath (PATH) was down 2.38% at $12.32. The stock trailed the S&P 500, which registered a daily gain of 0.07%. On the other hand, the Dow registered a loss of 0.7%, and ...

As agentic AI and the automation of workplace tasks become a bigger story in the second half, I think it’s becoming tough to ...

U.S. District Judge John Cronan for the Southern District of New York found that investors represented by Bleichmar Fonti & ...